Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586999 · ClinicalTrials.gov registry record · Phase 1
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03586999 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 18 participants.
The verdict
NCT03586999, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
Interventions
- DRUG Cyclophosphamide
- DRUG Nivolumab
- DRUG Etoposide
- DRUG Prednisolone
- DRUG Oncovin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03586999
The ClinicalTrials.gov registry entry for NCT03586999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03586999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03586999 about?
NCT03586999 is a clinical study titled "Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas". This regimen aims to become the first line treatment for peripheral T cell lymphoma, using nivolumab with the standard of care chemotherapy.
What is the current status of trial NCT03586999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-11-07. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT03586999?
The interventions under investigation include: Cyclophosphamide (DRUG), Nivolumab (DRUG), Etoposide (DRUG), Prednisolone (DRUG), Oncovin (DRUG).
Who is sponsoring clinical trial NCT03586999?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.